US FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022

 
• By Derrick Gingery
  
Fees up and down
Many generic and outsourcer user fees will increase in FY 2022, while biosimilar fees will remain steady or decrease. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics